Nutriband Inc. — Form 10-K Summary
Reporting period: Fiscal year ended January 31, 2017. The filing compares results with the period from January 4, 2016 (formation) through January 31, 2016, not a full prior fiscal year.
Business context
Nutriband is an early-stage company developing nutritional, cosmetic, and therapeutic transdermal patches. Its initial product lines are Energy, Weight Management, and Multivitamin patches. The company reported no product sales and had two executive employees. Products were being redeveloped with a U.S. contract manufacturer; the company described online sales and distributor outreach plans, but no distribution agreements had been obtained.
Key financial results and position
| Metric | FY ended Jan. 31, 2017 | Prior period |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative / selling, general and administrative expenses | $151,260 | $400 |
| Net loss | $151,260 | $400 |
| Operating cash flow | $(147,923) | $0 |
| Cash at period end | $27,124 | $100 |
The prior period covers only 28 days, so the expense and loss comparison is not period-aligned. Profit margins are not meaningful because the company had no revenue.
- Assets and liquidity: Current assets were $37,727, including $27,124 cash and $8,048 finished-goods inventory. Current liabilities were $14,618; working capital was positive $23,109.
- Debt: Total liabilities were $14,618, comprising $8,888 of interest-free related-party debt due on demand, $1,581 current long-term debt, and $4,149 accounts payable and accrued expenses. The remaining long-term debt was reported as zero.
- Cash flows and financing: Operating cash use of $147,923 was offset by $174,900 net financing cash flow, including $175,000 from common stock sales. Cash increased by $27,024 during the year.
- Equity: Stockholders’ equity was $23,109, versus a deficiency of $11,470 at January 31, 2016. Accumulated deficit was $177,464. The company issued 650,000 warrants in connection with stock sales; none were exercisable at year-end.
Material changes and outlook
The company moved manufacturing and operations to the United States after its January 2016 acquisition of Nutriband Ltd. It raised equity capital, acquired finished-goods inventory, and ended the year with higher cash and positive working capital, while recording a substantial operating loss and cash use. The CEO returned and cancelled 7,000,000 shares during the year.
Management estimated $85,000–$150,000 of capital requirements for the next 12 months and expected at least $85,000 of expenses. It said additional funding was necessary, with no financing arrangements in place, and warned that inability to raise funds could require curtailing operations or considering asset sales. Management also cited possible acquisition opportunities in pharmaceuticals, but no agreements had been consummated.
Risks, contingencies, and unusual items
- The auditor and management cited substantial doubt about the company’s ability to continue as a going concern, given recurring losses, no revenue, and dependence on additional financing. The audited financial statements were prepared on a going-concern basis.
- Management concluded disclosure controls and internal control over financial reporting were not effective as of January 31, 2017. The auditor did not attest to internal-control effectiveness.
- The company depended substantially on one contract manufacturer and had a quality-control agreement, but no formal manufacturing agreement governing broader commercial terms. The manufacturer did not have an FDA CGMP certificate; the company reported that the manufacturer advised its facility was compliant and had addressed FDA inspection comments.
- The filing describes regulatory uncertainty around transdermal supplement patches and states that the company had conducted no internal studies and no further formal testing of dosage or delivery time beyond a manufacturer-provided caffeine test conducted at Rutgers University.
- Other stated risks include limited operating history, competition and uncertain consumer acceptance, dependence on the CEO, cyber risks, and the absence of a public market for the common stock. No legal proceedings or material subsequent events were reported.
Important facts for investors to verify
- Whether the company has since secured sufficient financing to meet its stated $85,000–$150,000 capital needs and address the going-concern uncertainty.
- Whether products generated sales, achieved distribution agreements, or received further efficacy and safety testing after the reporting date.
- Whether a formal manufacturing agreement was executed and what quality, regulatory, pricing, and supply protections it provides.
- Whether disclosure controls and internal controls have been remediated, and whether the company has developed a trading market for its shares.
- The filing’s financial statements report an accumulated deficit of $177,464, while the MD&A narrative cites $177,469; investors should confirm the correct figure in the audited statements and any subsequent filings.